Search

Your search keyword '"John C. Hodges"' showing total 2 results
Start Over Author "John C. Hodges" Publisher informa healthcare
2 results on '"John C. Hodges"'

1. Overview Cardiovascular & Renal: Angiotensin antagonists: agents that interact with the AT2 receptor and their potential therapeutic utilities

Author

John C. Hodges

Subjects
Pharmacology, endocrine system, Angiotensin II receptor type 1, Patent literature, General Medicine, respiratory system, Biology, Drug Discovery, cardiovascular system, Angiotensin receptor antagonist, Receptor, Angiotensin AT2 Receptor, hormones, hormone substitutes, and hormone antagonists, circulatory and respiratory physiology
Abstract

The primary and patent literature (through mid-1994) describing advances in AT2 receptor molecular biology and agents that interact with the angiotensin AT2 receptor subtype is reviewed. In vitro structure-activity relationships are summarised for both AT2-specific antagonists and balanced AT1/AT2 antagonists. Literature reports describing functional correlates for AT2 receptors are tabulated, and potential therapeutic utilities resulting from pharmacological intervention at AT2 receptors are discussed.

Published
1994
Full Text
View/download PDF

2. Patent reform in the US: what's at stake for pharmaceutical innovation?

Author

Yancey A and Stewart CN Jr

Subjects
Biomedical Research economics, Drug Design, Drug Industry economics, Pharmaceutical Preparations economics, Time Factors, United States, Clinical Trials as Topic methods, Drug Industry legislation & jurisprudence, Patents as Topic legislation & jurisprudence
Abstract

The current patent landscape in the US has not undergone major legislative reform since 1952. The US Senate version of the most recently proposed patent reform legislation puts forward a number of rule changes that could impact the pharmaceutical industry. Among the bill's major provisions are moving to a first-to-file system, changes to post-grant review and reexamination procedures, and damages reform. Various industries with a stake in patent reform have responded to the proposed changes. The need for balanced reform makes the stakes particularly high for the pharmaceutical industry which must invest a significant amount of time and money in the research and development process in exchange for already abbreviated patent lifetimes due to the lengthy clinical trial process.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results